Why the study?
Does CRT-D have a different prognostic effect and microRNA expression profile in T2DM patients with heart failure compared to nondiabetic patients?
Does CRT-D have a different prognostic effect and microRNA expression profile in T2DM patients with heart failure compared to nondiabetic patients?
This review summarizes literature on the prognostic effects and microRNA changes associated with CRT-D in heart failure patients with type 2 diabetes compared to those without diabetes.
May identify miR signatures for CRT response prediction in HF with T2DM; leaves open validation in prospective trials.
Heart failure (HF) and type 2 diabetes mellitus (T2DM) are two growing and related diseases in general population and particularly in elderly people. In selected patients affected by HF and severe dysfunction of left ventricle ejection fraction (LVEF), with left bundle brunch block, the cardiac resynchronization therapy with a defibrillator (CRT) is the treatment of choice to improve symptoms, NYHA class, and quality of life. CRT effects are related to alterations in genes and microRNAs (miRs) expression, which regulate cardiac processes involved in cardiac apoptosis, cardiac fibrosis, cardiac hypertrophy and angiogenesis, and membrane channel ionic currents. Different studies have shown a different prognosis in T2DM patients and T2DM elderly patients treated by CRT-D. We reviewed the literature data on CRT-D effect on adult and elderly patients with T2DM as compared with nondiabetic patients.
No takes yet. Share an insight, caveat, or question.
Sardu et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: